Trevi Files US$149.2m Shelf Registration Amid Wider Quarterly Losses
Trevi Therapeutics’ wider quarterly loss coincides with a new US$149.2 million shelf registration to sell up to 8,000,000 shares. The filing is linked to its earnings release and ongoing trial commitments, and the analysis suggests the registration could offset losses. The outlook is still tied to future revenue and earnings projections into 2029.